Philip Liebson to Cardiovascular Diseases
This is a "connection" page, showing publications Philip Liebson has written about Cardiovascular Diseases.
Connection Strength
1.162
-
Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk. Prev Cardiol. 2009; 12(1):43-50.
Score: 0.235
-
Cardiovascular risk in special populations: overview. Prev Cardiol. 2009; 12(3):121-7.
Score: 0.235
-
ENHANCE and ONTARGET. Prev Cardiol. 2008; 11(3):179-82.
Score: 0.219
-
VALIANT and EUROPA. Prev Cardiol. 2004; 7(1):42-4.
Score: 0.166
-
Development and Validation of Risk Prediction Models for Cardiovascular Events in Black Adults: The Jackson Heart Study Cohort. JAMA Cardiol. 2016 04 01; 1(1):15-25.
Score: 0.097
-
Cardiovascular disease in special populations III: stroke. Prev Cardiol. 2010; 13(1):1-7.
Score: 0.063
-
Comparison of the prognostic value of left ventricular hypertrophy in African-American men versus women. Am J Cardiol. 2004 Dec 01; 94(11):1383-90.
Score: 0.044
-
Transesophageal echocardiography in critically ill patients: what is the intensivist's role? Crit Care Med. 2002 May; 30(5):1165-6.
Score: 0.037
-
Optimal antihypertensive therapy for prevention and treatment of left ventricular hypertrophy. Curr Hypertens Rep. 2000 Jun; 2(3):260-70.
Score: 0.032
-
Clinical correlates and prognostic significance of change in standardized left ventricular mass in a community-based cohort of African Americans. J Am Heart Assoc. 2015 Feb 05; 4(2).
Score: 0.022
-
Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy. Am J Cardiol. 2004 Jun 03; 93(11A):32C-48C.
Score: 0.011